1461094004-fc91a5ed-e358-482f-9823-93a215c34ac4

1. A method of treating a mammal to reduce symptoms or to delay onset of Clostridium difficile infection or to reduce or prevent Clostridium difficile mediated intestinal damage, comprising:
administering to a mammal an oligosaccharide having a structure galactose-\u03b1-1-3-galactose-\u03b2-4-N-acetyl-D-glucosamine and comprising one or more side chains.
2. The method of claim 1 wherein the side chain is a fucose moiety.
3. The method of claim 1 wherein the side chain is an \u03b12-linked fucose moiety.
4. The method of claim 1 wherein the side chain is an \u03b13-linked fucose moiety.
5. The method of claim 1 wherein the oligosaccharide is covalently attached to a non-absorbable polymer.
6. The method of claim 1 wherein the mammal is a human.
7. The method of claim 1 wherein the mammal is a farm animal.
8. The method of claim 1 wherein the mammal is a companion animal.
9. The method of claim 1 wherein the mammal is infected with C. difficile.
10. The method of claim 1 wherein the mammal is at risk of infection with C. difficile.
11. The method of claim 1 wherein the agent is glycan no. 103.
12. The method of claim 6 wherein the human is hospitalized.
13. The method of claim 6 wherein the human is immunosuppressed.
14. The method of claim 6 wherein the human is a transplant recipient.
15. The method of claim 6 wherein the human is HIV positive.
16. The method of claim 6 wherein the human has been treated with clindamycin.
17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an agent comprising an oligosaccharide having a structure galactose-\u03b1-1-3-galactose-\u03b2-1-4-N-acetyl-D-glucosamine and comprising one or more side chains.
18. The pharmaceutical composition of claim 17 wherein the carrier is a liquid.
19. The pharmaceutical composition of claim 17 wherein the carrier is a solid.
20. The pharmaceutical composition of claim 17 further comprising a non-absorbable polymer.
21. The pharmaceutical composition of claim 17 wherein the oligosaccharide is attached to the non-absorbable polymer.
22. The pharmaceutical composition of claim 17 wherein the agent is glycan no. 103.
23. The pharmaceutical composition of claim 17 further comprising an antibiotic to which Clostridium difficile is sensitive.
24. The pharmaceutical composition of claim 22 wherein the antibiotic is metronidazole.
25. The pharmaceutical composition of claim 22 wherein the antibiotic is vancomycin.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of producing a genetically modified plant characterized as having increased growth and yield as compared to the corresponding wild-type plant, said method comprising:
contacting a plant cell with a nucleic acid sequence comprising a regulatory sequence, wherein said regulatory sequence is operably associated with a nucleic acid encoding a cyclin protein, to obtain a transformed plant cell;
producing plants from said transformed plant cell; and
selecting a plant exhibiting said increased yield.
2. The method of claim 1, wherein the genetically modified plant exhibits increased root growth.
3. The method of claim 1, wherein the genetically modified plant exhibits increased shoot growth.
4. The method of claim 1, wherein the cyclin is cyc1aAt.
5. The method of claim 1, wherein the regulatory sequence comprises a cycB1a;At promoter.
6. The method of claim 5, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO: 1.
7. The method of claim 6, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 1148.
8. The method of claim 6, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 286.
9. The method of claim 6, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 205.
10. The method of claim 1, wherein the contacting is by physical means.
11. The method of claim 1, wherein the contacting is by chemical means.
12. The method of claim 1, wherein the plant cell is selected from the group consisting of protoplasts, gamete producing cells, and cells which regenerate into whole plants.
13. The method of claim 1, wherein said nucleic acid is contained in a T-DNA derived vector.
14. A plant produced by the method of claim 1.
15. Plant tissue derived from a plant produced by the method of claim 1.
16. A seed derived from a plant produced by the method of claim 1.
17. A transformed plant cell comprising a chimeric nucleic acid sequence comprising:
a cycB1a;At regulatory sequence operably linked to a heterologous nucleic acid sequence.
18. The transformed plant cell of claim 17, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1.
19. The transformed plant cell of claim 18, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 1148.
20. The transformed plant cell of claim 18, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 286.
21. The transformed plant cell of claim 18, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 205.
22. A transgenic plant comprising a heterologons nucleic acid sequence regulated by a regulatory sequence of cycB1a;At wherein the regulatory sequence is operably linked to the heterologous nucleic acid sequence.
23. The transgenic plant of claim 22, wherein the regulatory sequence has the sequence set forth in SEQ ID NO:1.
24. The transgenic plant of claim 23, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 1148.
25. The transgenic plant of claim 23, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 286.
26. The transgenic plant of claim 23, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 205.
27. An isolated nucleic acid sequence comprising a functional cycB1a;At regulatory sequence.
28. The sequence of claim 27, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1.
29. The sequence of claim 28, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 1148.
30. The sequence of claim 28, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 351.
31. The sequence of claim 28, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 286.
32. The sequence of claim 28, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 205.
33. The sequence of claim 28, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 120.
34. The sequence of claim 28, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 60.
35. A nucleic acid sequence comprising a functional cycB1a;At regulatory sequence, operably linked to a nucleic acid sequence encoding a cyclin protein.
36. A vector containing the nucleic acid sequence of claim 27 or 35.
37. The nucleic acid sequence of claim 35, wherein said regulatory sequence comprises the sequence set forth in SEQ ID NO:1.
38. The nucleic acid sequence of claim 37, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 1148.
39. The nucleic acid sequence of claim 37, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 351.
40. The nucleic acid sequence of claim 37, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 286.
41. The nucleic acid sequence of claim 37, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 205.
42. The nucleic acid sequence of claim 37, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 120.
43. The nucleic acid sequence of claim 37, wherein the regulatory sequence comprises the sequence set forth in SEQ ID NO:1 from about nucleotide 1 to about nucleotide 60.